ChromaDex: Difference between revisions
LilianaUwU (talk | contribs) Reverted 3 edits by Health.Science.24 (talk): Bunch of spam |
Updated to current info Tags: references removed Visual edit |
||
| Line 16: | Line 16: | ||
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.<ref name="deathmatch">{{cite web|url=https://medium.com/neodotlife/elysium-and-basis-vs-chromadex-and-tru-niagen-10264fca0bdb|last1=Weintraub|first1=Karen|title=The Life Extension Death Match|work=NEO.LIFE}}</ref> ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref> |
In 2011, ChromaDex licensed patents from [[Dartmouth College]], [[Cornell University]], and [[Washington University in St. Louis]] regarding [[nicotinamide riboside]], which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.<ref name="deathmatch">{{cite web|url=https://medium.com/neodotlife/elysium-and-basis-vs-chromadex-and-tru-niagen-10264fca0bdb|last1=Weintraub|first1=Karen|title=The Life Extension Death Match|work=NEO.LIFE}}</ref> ChromaDex licensed patents from the University of Mississippi and the [[USDA]] to commercially develop [[pterostilbene]] and sell the compound under the brand name pTeroPure.<ref name="DM">{{cite web |url=http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |title=Ole Miss grants exclusive patent rights to ChromaDex Corp. |accessdate=2012-05-25 |last=Neeb |first=Matthew |date=2011-06-20 |work= |publisher=The Daily Mississippian |pages= |quote= |archive-url=https://web.archive.org/web/20120418075931/http://thedmonline.com/article/ole-miss-grants-exclusive-patent-rights-chromadex-corp |archive-date=2012-04-18 |url-status=dead }}</ref> ChromaDex no longer sells pTeroPure.<ref>{{Cite web|title=ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol|url=http://www.nutritionaloutlook.com/article/chromadex-ceases-new-pterostilbene-orders-based-research-demonstrating-increase-ldl|last=Krawiec|first=Sebastian|date=2018-10-31|website=Nutritional Outlook|language=en|access-date=2020-05-01}}</ref> |
||
ChromaDex also licensed patents from the University of Mississippi on Immulina, a proprietary extract of ''Arthrospira platensis'' (or spirulina, a type of algae) which it continues to sell today as an ingredient for use in dietary supplements. |
|||
[[Elysium Health]] bought the ingredients in its "Basis" product from ChromaDex.<ref name=Wired>{{cite news|last1=Zhang|first1=Sarah|title=The Weird Business Behind a Trendy "Anti-Aging" Pill|url=https://www.wired.com/2016/07/confused-elysiums-anti-aging-drug-yeah-fda/|work=Wired|date=July 6, 2016}}</ref> The two firms had an agreement under which Elysium didn't have to acknowledge ChromaDex as the source of the ingredients, but then after Elysium recruited the VP of business development from ChromaDex and stopped paying ChromaDex, ChromaDex sued Elysium and the information became public.<ref name=TC>{{cite news|last1=Buhr|first1=Sarah|title=A new lawsuit alleges anti-aging startup Elysium Health hasn’t paid its sole supplier|url=https://techcrunch.com/2017/01/16/a-new-lawsuit-alleges-anti-aging-startup-elysium-health-hasnt-paid-its-supplier-and-is-in-breach-of-agreement/|work=TechCrunch|date=January 16, 2017}}</ref> |
|||
== History == |
|||
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on NR in 2012, leading to the commercialization of Niagen in 2013. |
|||
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018. |
|||
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone NR supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million, led by Horizons Ventures, the investment firm of Hong Kong billionaire Li Ka-Shing, as well as venture capitalists and strategic investors, including ICONIQ Capital, to support research and development, and global expansion. |
|||
== Niagen NR Clinical Studies == |
|||
Niagen, the active ingredient in Tru Niagen, is the only patented form of NR that has been extensively studied in published human clinical trials [4–24]. |
|||
Thirteen peer-reviewed clinical studies using Niagen have been published in high-tiered biomedical journals, demonstrating an increase in NAD+* [1–10,18,19,21]. These 13 clinical studies include the first-ever clinical NR trial supporting its bioavailability, safety, and efficacy, the pharmacokinetics of NR supplementation in humans, NR’s dose-response effect on blood NAD+ levels, as well as the health benefits of NR supplementation, including improvements in cardiovascular health, liver health, body composition, and mitochondrial function. |
|||
Because the safety profile of Niagen is established, validated, and vetted, numerous additional studies in humans are ongoing or have recently completed (as of December 2022). More specifically, an additional 40+ completed or ongoing clinical trials investigating NR only are currently registered on www.clinicaltrials.gov. |
|||
== Research Initiatives == |
|||
The ChromaDex External Research Program (CERP <sup>TM</sup>) is setting the industry standard for excellence in collaborative research on NAD+. Through CERP , ChromaDex partners with independent,third-party leading universities and research institutions worldwide and upon request, donates Niagen, one of the most studied and efficient modern NAD+ precursors in the healthy aging space, and other materials in bulk, via material transfer agreements (MTAs) to uncover the full potential of NAD+. |
|||
CERP is leading the industry in promoting and supporting NAD+ research. CERP doesn’t limit material donations to studies that will demonstrate a business benefit to ChromaDex, and supports research outside of the framework for dietary supplements. Research through CERP is primarily independently driven, and ChromaDex only provides protocol recommendations, based upon non-public expertise, to improve the likelihood of success. ChromaDex does not alter or influence data analysis, data interpretation, or publication rights. |
|||
In addition to receiving material donations thoroughly tested by the ChromaDex QA & QC teams via MTA for research, these investigators receive additional benefits through CERP including receiving technical support to help improve the likelihood of success of their research, and MTA language that encourages the investigator and institution to develop and own intellectual property. |
|||
CERP has proven to be beneficial to all researchers and product developers in the NAD+ space, including direct competitors, but research from the program has demonstrated that NAD+ supplementation promotes cellular health and may be beneficial to vulnerable health populations. Recent clinical research advances through CERP have demonstrated significantly lower NAD+ levels in age-related conditions including heart disease, Parkinson’s disease, ataxia telangiectasia (AT), autoimmune disorders, and others, while demonstrating NAD-boosting benefits following supplementation with Niagen. This body of research is still growing, and further investigation is needed to determine to what extent Niagen supplementation affects these health outcomes. |
|||
In January 2022, CERP celebrated its 100th published peer-reviewed study on the company’s flagship ingredient Niagen and other materials. |
|||
In Apri 2022, ChromaDex announced the achievement of its 250th external research agreement. |
|||
== Partnerships and Joint Ventures == |
|||
In June 2022, ChromaDex signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China, and in November 2022 the company announced an agreement to launch a joint venture (JV) in the same territory. China’s marketplace can benefit greatly from Tru Niagen, with more than 260 million people over the age of 60. |
|||
A new partnership with MyPharma2Go was formed to conduct cross-border sales of Tru Niagen in Brazil—the first Latin American country to welcome the brand. |
|||
ChromaDex announced a new supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). |
|||
ChromaDex and Nestlé Health Science announced a new Niagen commercial supply agreement and $5 million investment. |
|||
In 2022, ChromaDex launched a Tru Niagen partnership with ShopHQ, a multiplatform interactive television network with live TV programming that reaches roughly 90 million U.S. homes, and influencer Danny Seo, an authoritative voice on living a healthy, natural, good-for-you life. |
|||
In 2022, ChromaDex partnered with Juvenis for cross-border sales of Tru Niagen into South Korea. |
|||
In 2018, ChromaDex announced a Tru Niagen partnership with Watsons, the leading health and beauty retailer in Asia and Europe. |
|||
In 2021, Tru Niagen launched in 3,800 Walmart stores across the United States. |
|||
In 2021, ChromaDex and Health & Happiness (H&H) Group announced a supply agreement for Niagen, in which H&H Group expanded the Swisse® healthy aging product line into the growing NAD+ space with Niagen. |
|||
== Awards == |
|||
NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP) with a '''2022 European NutraIngredients Award''' in the “Nutrition Research Project” category for developing the science behind patented Niagen. In 2019, NutraIngredients awarded Tru Niagen the Ingredient of the Year award in the Healthy Aging category. |
|||
Tru Niagen is one of Amazon U.S.’s top-selling brands in the vitamin B3 category for boosting NAD<sup>+</sup> levels as of December 2022. |
|||
==References== |
==References== |
||
Revision as of 02:26, 24 February 2023
 | |
| Company type | Public |
|---|---|
| Nasdaq: CDXC Russell 2000 Index component | |
| Industry | Dietary supplements, food ingredients, chemical sample analysis |
| Founded | 1999 |
| Headquarters | Los Angeles, California, United States |
Key people | Rob Fried (CEO) Frank Jaksch (Co-Founder, Executive Chairman) |
| Products | Tru Niagen |
| Website | www |
ChromaDex is a dietary supplement and food ingredient company based in Los Angeles, California founded in 1999 that is publicly traded on the NASDAQ.
In 2011, ChromaDex licensed patents from Dartmouth College, Cornell University, and Washington University in St. Louis regarding nicotinamide riboside, which it markets and sells as an ingredient under the brand name Niagen and sells directly to consumers as Tru Niagen.[1] ChromaDex licensed patents from the University of Mississippi and the USDA to commercially develop pterostilbene and sell the compound under the brand name pTeroPure.[2] ChromaDex no longer sells pTeroPure.[3]
ChromaDex also licensed patents from the University of Mississippi on Immulina, a proprietary extract of Arthrospira platensis (or spirulina, a type of algae) which it continues to sell today as an ingredient for use in dietary supplements.
History
Founded in 1999 by Frank Jaksch, ChromaDex first acquired licensed Dartmouth patents on NR in 2012, leading to the commercialization of Niagen in 2013.
ChromaDex is traded on the NASDAQ (as CDXC) as of April 2016 and was added to the U.S. Small Cap Russell 2000 Index in June 2018.
In 2017, the company acquired HealthSpan Research LLC and its product Tru Niagen, a standalone NR supplement, sold direct to U.S. consumers. Also in 2017, ChromaDex raised $48 million, led by Horizons Ventures, the investment firm of Hong Kong billionaire Li Ka-Shing, as well as venture capitalists and strategic investors, including ICONIQ Capital, to support research and development, and global expansion.
Niagen NR Clinical Studies
Niagen, the active ingredient in Tru Niagen, is the only patented form of NR that has been extensively studied in published human clinical trials [4–24].
Thirteen peer-reviewed clinical studies using Niagen have been published in high-tiered biomedical journals, demonstrating an increase in NAD+* [1–10,18,19,21]. These 13 clinical studies include the first-ever clinical NR trial supporting its bioavailability, safety, and efficacy, the pharmacokinetics of NR supplementation in humans, NR’s dose-response effect on blood NAD+ levels, as well as the health benefits of NR supplementation, including improvements in cardiovascular health, liver health, body composition, and mitochondrial function.
Because the safety profile of Niagen is established, validated, and vetted, numerous additional studies in humans are ongoing or have recently completed (as of December 2022). More specifically, an additional 40+ completed or ongoing clinical trials investigating NR only are currently registered on www.clinicaltrials.gov.
Research Initiatives
The ChromaDex External Research Program (CERP TM) is setting the industry standard for excellence in collaborative research on NAD+. Through CERP , ChromaDex partners with independent,third-party leading universities and research institutions worldwide and upon request, donates Niagen, one of the most studied and efficient modern NAD+ precursors in the healthy aging space, and other materials in bulk, via material transfer agreements (MTAs) to uncover the full potential of NAD+.
CERP is leading the industry in promoting and supporting NAD+ research. CERP doesn’t limit material donations to studies that will demonstrate a business benefit to ChromaDex, and supports research outside of the framework for dietary supplements. Research through CERP is primarily independently driven, and ChromaDex only provides protocol recommendations, based upon non-public expertise, to improve the likelihood of success. ChromaDex does not alter or influence data analysis, data interpretation, or publication rights.
In addition to receiving material donations thoroughly tested by the ChromaDex QA & QC teams via MTA for research, these investigators receive additional benefits through CERP including receiving technical support to help improve the likelihood of success of their research, and MTA language that encourages the investigator and institution to develop and own intellectual property.
CERP has proven to be beneficial to all researchers and product developers in the NAD+ space, including direct competitors, but research from the program has demonstrated that NAD+ supplementation promotes cellular health and may be beneficial to vulnerable health populations. Recent clinical research advances through CERP have demonstrated significantly lower NAD+ levels in age-related conditions including heart disease, Parkinson’s disease, ataxia telangiectasia (AT), autoimmune disorders, and others, while demonstrating NAD-boosting benefits following supplementation with Niagen. This body of research is still growing, and further investigation is needed to determine to what extent Niagen supplementation affects these health outcomes.
In January 2022, CERP celebrated its 100th published peer-reviewed study on the company’s flagship ingredient Niagen and other materials.
In Apri 2022, ChromaDex announced the achievement of its 250th external research agreement.
Partnerships and Joint Ventures
In June 2022, ChromaDex signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China, and in November 2022 the company announced an agreement to launch a joint venture (JV) in the same territory. China’s marketplace can benefit greatly from Tru Niagen, with more than 260 million people over the age of 60.
A new partnership with MyPharma2Go was formed to conduct cross-border sales of Tru Niagen in Brazil—the first Latin American country to welcome the brand.
ChromaDex announced a new supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs).
ChromaDex and Nestlé Health Science announced a new Niagen commercial supply agreement and $5 million investment.
In 2022, ChromaDex launched a Tru Niagen partnership with ShopHQ, a multiplatform interactive television network with live TV programming that reaches roughly 90 million U.S. homes, and influencer Danny Seo, an authoritative voice on living a healthy, natural, good-for-you life.
In 2022, ChromaDex partnered with Juvenis for cross-border sales of Tru Niagen into South Korea.
In 2018, ChromaDex announced a Tru Niagen partnership with Watsons, the leading health and beauty retailer in Asia and Europe.
In 2021, Tru Niagen launched in 3,800 Walmart stores across the United States.
In 2021, ChromaDex and Health & Happiness (H&H) Group announced a supply agreement for Niagen, in which H&H Group expanded the Swisse® healthy aging product line into the growing NAD+ space with Niagen.
Awards
NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP) with a 2022 European NutraIngredients Award in the “Nutrition Research Project” category for developing the science behind patented Niagen. In 2019, NutraIngredients awarded Tru Niagen the Ingredient of the Year award in the Healthy Aging category.
Tru Niagen is one of Amazon U.S.’s top-selling brands in the vitamin B3 category for boosting NAD+ levels as of December 2022.
References
- ^ Weintraub, Karen. "The Life Extension Death Match". NEO.LIFE.
- ^ Neeb, Matthew (2011-06-20). "Ole Miss grants exclusive patent rights to ChromaDex Corp". The Daily Mississippian. Archived from the original on 2012-04-18. Retrieved 2012-05-25.
- ^ Krawiec, Sebastian (2018-10-31). "ChromaDex ceases new pterostilbene orders based on research demonstrating increase in LDL cholesterol". Nutritional Outlook. Retrieved 2020-05-01.